Screened  
\( n = 1324 \)

Randomized  
\( n = 822 \)

NVA237  
\( n = 552 \)

Discontinued: 102 (18.5%)
- Withdrew consent 38 (37.3%)
- Adverse event 30 (29.4%)
- Administrative problems 21 (20.6%)
- Unsatisfactory therapeutic effect 5 (4.9%)
- Protocol deviation 4 (3.9%)
- Death 2 (2.0%)
- Lost to follow up 1 (1.0%)
- Patient’s inability to use device 1 (1.0%)

Completed Week 26  
\( n = 450 (81.5\%) \)

Placebo  
\( n = 270 \)

Discontinued: 58 (21.5%)
- Withdrew consent 14 (24.1%)
- Adverse event 16 (27.6%)
- Administrative problems 13 (22.4%)
- Unsatisfactory therapeutic effect 5 (8.6%)
- Protocol deviation 3 (5.2%)
- Death 3 (5.2%)
- Lost to follow up 2 (3.4%)
- Patient’s inability to use device 1 (1.7%)
- Patient no longer requires study drug 1 (1.7%)